Thrombin-Activatable Fibrinolysis Inhibitor in Stable Angina Pectoris
Annotatsiya
Impairment of endogenous fibrinolysis is considered a component of residual atherothrombotic risk. Data regarding the thrombin-activable fibrinolysis inhibitor (TAFI) in the context of chronic coronary syndromes remain inconsistent. This study aimed to evaluate the levels of TAFI and related hemostatic factors in patients with stable angina, determine their variation across functional classes, and describe the one-year clinical course of a specific subgroup characterized by high TAFI levels. Elevated levels of TAFI and associated hemostatic factors are linked to a higher functional class of stable angina. These findings support the need for prospective validation of TAFI, utilizing individual patient data, standardized clinical endpoints, and multivariable adjustment.
Hali tarjima qilinmagan